AstraZeneca cops to rare, deadly side effect of COVID jab as lawsuits mount (msn.com)

Lawyers representing “dozens” of class-action claimants say some of their clients’ cases could be worth as much as $25 million, calling the Cambridge-headquartered pharma firm’s vaccine “a defective product,” according to the Daily Mail.

AstraZeneca, which is contesting the claims, acknowledged in a February legal document that its vaccine can “in very rare cases” cause a condition called thrombosis with thrombocytopenia syndrome, or TTS.